先为达生物GLP-1新药申报上市近日,先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局(NMPA)受理,用于成人2型糖尿病患者血糖控制适应症。根据先为达生物公开资料,伊诺格鲁肽是一种新型、脂肪酸修饰的长效GLP-1受体激动剂,只需每周皮下注射一次。该产品已完成糖尿病、减重的3期临床研究,部分结果在美国糖尿病大会、欧洲糖尿病大会先后发表,朱大龙...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.